En este artículo:
Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on the shares. The discontinuation of the Alpha-1 Antitrypsin Deficiency program “makes sense” given the changing landscape, the analyst tells investors. Wells continues to think ATTR amyloidosis with cardiomyopathy is the main value driver and sees quick enrollment in the Phase 3 trial as a promising sign of patient acceptance of gene editing.
Stay Ahead of the Market:
-
Discover outperforming stocks and invest smarter with Top Smart Score Stocks
-
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NTLA:
-
Intellia Therapeutics announces net workforce reduction of 27% in 2025
-
Intellia Therapeutics announces retirement of CSO Laura Sepp-Lorenzino
-
Intellia Therapeutics: Phase 3 HAELO study to complete enrollment in 2H25
-
Intellia Therapeutics price target lowered to $47 from $54 at RBC Capital
-
Intellia Therapeutics price target lowered to $50 from $58 at BofA